TCAI first US pulsed field ablation trial
Analysis based on 13 articles · First reported Jul 20, 2026 · Last updated Sep 02, 2026
The trial could accelerate adoption of pulsed field ablation technology, potentially benefiting medical device manufacturers and improving patient outcomes. However, as an early-stage clinical trial, its immediate market impact is limited.
The Texas Cardiac Arrhythmia Institute (TCAI) at St. David s Medical Center became the first facility in the United States to participate in a clinical trial evaluating a next-generation mapping and pulsed field ablation system for treating paroxysmal and persistent atrial fibrillation. Andrea Natale, executive medical director of TCAI and global principal investigator, performed the first procedure. Pulsed field ablation uses electric fields to ablate targeted heart tissue, potentially reducing damage to surrounding structures compared to traditional thermal ablation. The system also incorporates advanced 3D cardiac mapping technology. This trial aims to assess the safety and effectiveness of the technology, which could represent a significant advancement in electrophysiology.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard